Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

Cherry Biolabs GmbH

Cherry Biolabs is a spin-off from the University Hospital Würzburg. The company holds the exclusive license for the Hemibody platform technology granted by the University Würzburg. Cherry Biolabs' lead program is a Hemibody pair designed to eliminate Multiple Myeloma. The company seeks to build an internal drug pipeline and to license out the technology on a target-specific basis. The program to develop the Hemibody technology was funded by the "Bavarian m4 Award", the "GO-Bio Gründungsoffensive Biotechnologie" from the German Federal Ministry of Education and Research, the Comprehensive Cancer Center Mainfranken (CCC) in Würzburg and the society "Hilfe im Kampf gegen Krebs e.V." *


Period Start 2019-01-01 established (s-off
  Predecessor University Hospital Würzburg (Universitätsklinikum Würzburg)
Products Industry BIOTECH
  Industry 2 Hemibody technology
Person Person Stuhler, Gernot (Cherry Biolabs 202011 CEO + Founder + Prof at Univ Hospital Würzburg)
Region Region Würzburg
  Country Germany
  Street 15 Friedrich-Bergius-Ring
  City 97076 Würzburg
  Tel +49-931-201-444-23
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: MorphoSys AG. (11/11/20). "Press Release: MorphoSys and Cherry Biolabs Announce Licensing of Hemibody Technology". Planegg & Würzburg.
Record changed: 2021-04-22


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Cherry Biolabs GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC C Lee Hood Speaking 650x300px

» top